Navigation Links
Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease
Date:4/15/2008

ause Alzheimer's disease," said Dr. O'Nuallain. "These initial findings could be promising in Alzheimer's disease research using naturally occurring antibodies."

The oral presentation at AAN, entitled "Affinity Isolation and Characterization of Abeta Conformer-Reactive Antibodies Contained in Human Immune Globulin (IVIG)," showed that GAMMAGARD contains naturally occurring antibodies that directly bind to different forms of beta-amyloid protein, including oligomers and fibrils.

"Observations from this study provide insight into how GAMMAGARD LIQUID may be of potential clinical benefit for Alzheimer's patients," said Dave Morgan, director of Neuroscience Research, University of South Florida. "This study suggests that GAMMAGARD LIQUID may target the primary pathway involved in Alzheimer's disease and justifies additional studies to evaluate whether GAMMAGARD LIQUID can effectively reverse the effects of Alzheimer's disease."

According to the Alzheimer's Association, an estimated 5.2 million Americans have Alzheimer's disease, including one out of eight people age 65 and older, and the number of new cases per year is expected to grow to 454,000 by 2010. No cure currently exists that can halt or delay the brain deterioration associated with Alzheimer's disease, but new research shows encouraging results. The study's findings showed how the mechanism of action of GAMMAGARD may work on multiple forms of the beta-amyloid peptide to protect the human brain from dementia and may facilitate the development of treatment for patients with Alzheimer's disease.

Additional GAMMAGARD Trials in Alzheimer's Disease

At the AAN meeting, other studies will be presented on the use of GAMMAGARD in Alzheimer's disease. One oral presentation scheduled for April 17 - "A Double-Blind, Placebo-Controlled, Phase II Clinical Trial of Intravenous Immunoglobulin (IVIG) for Treatment of Alzheimer's Disease" - will discuss the evaluation of the efficacy, tolerabil
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... December 11 Algeta ASA (OSE: ... first clinical center in the,US, the Tulane ... patients,in the phase III clinical study of ... hormone-refractory) prostate cancer,(CRPC) that has metastasized to ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) ...
(Date:12/10/2009)... Dec. 10 Dendreon Corporation (Nasdaq: DNDN ... public offering of 15,000,000 shares of its common stock ... share. Dendreon also granted to the underwriters a ... shares of common stock to cover overallotments, if any. ... 15, 2009, subject to customary closing conditions. ,, J. ...
(Date:12/10/2009)... -- Newly published research, by investigators, at ... (NESCI) in the journal STEM CELLS reported ... with "Limbal Stem Cell Deficiency" (LSCD) using ... need of suppressing their immunity. ,, ... a painful, blinding disease that requires long-term, ...
(Date:12/10/2009)... /PRNewswire-Asia/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: ... developer and,producer of prescription drugs and licensed ... Republic of China ("PRC"), today reported that,effective ... operating entity of Lotus,appointed Mr. Jinzhong HAN ... Drug division ("OTC Division"). , ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3
... of content management systems (CMS) providers, Northwoods Software ... clients. Forget the gearhead techno-speak. The Milwaukee area firm ... through plain talk and better Web design. , ,We ... said Pat Bieser, founder and CEO of the Brown ...
... University of Wisconsin-Madison received their grades online for the first ... implemented by a team of staff members from the Universitys ... of the Registrar . , ,We worked out ... what we would release to instructors, said Connie Chatman, manager ...
... agencies have backed a new organization, the Wisconsin Angel ... , ,Wisconsin excels in researching and developing cutting-edge technology ... first and most critical stage, said Governor ... , ,The Wisconsin Technology Council , which advises ...
Other Biology Technology:Untangling the Web: Northwoods Software in profile 2Untangling the Web: Northwoods Software in profile 3Untangling the Web: Northwoods Software in profile 4Untangling the Web: Northwoods Software in profile 5UW-Madisons move to online grading goes smoothly 2
(Date:12/14/2009)... defining feature of humans. That,s until examples of tool use ... array of other mammals. Now, a report in the December ... publication, adds an octopus to the growing list of tool ... trick that the researchers call stilt walking. In it, the ... makes its eight arms rigid, and raises the whole assembly ...
(Date:12/14/2009)... Dec. 14 MODA Technology Partners, a ... utility and product testing for the Pharmaceutical industry, ... the company,s third generation mobile data acquisition platform. ... to further automate their regulated manufacturing processes. ... ,, Fully-Configurable Test Methods: Each ...
(Date:12/13/2009)... Biologists have identified plant enzymes that may help to ... to use water more efficiently. The finding could help ... gases. , Plants take in the carbon dioxide they ... surface of leaves. But for each molecule of the ... these same openings. The pores can tighten to save ...
Breaking Biology News(10 mins):Tool use in an invertebrate: The coconut-carrying octopus 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3The MedZilla Report for July 2009 Health Care Creates 20 000 More Jobs As Economy Hits Insurers 13517 1The MedZilla Report for July 2009 Health Care Creates 20 000 More Jobs As Economy Hits Insurers 13517 2The MedZilla Report for July 2009 Health Care Creates 20 000 More Jobs As Economy Hits Insurers 13517 3The MedZilla Report for July 2009 Health Care Creates 20 000 More Jobs As Economy Hits Insurers 13517 4Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates 54282 1Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates 54282 2Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates 54282 3Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates 54282 4The tourist trap 9540 1
... of molecular and human genetics at Baylor College of Medicine, ... bacteria stressed by starvation, sometimes resulting in a rare change ... report in the current issue of the journal Molecular Cell, ... but also show that this only occurs at a special ...
... the Public Health Agency of Canada - with assistance ... Diseases - have developed vaccines against the Ebola and ... in non-human primates. , In a study published in ... and Dr. Steven Jones of PHAC's National Microbiology Laboratory ...
... prediction. , Computers can predict the detailed structure of ... least some of the time, according to new studies ... which were reported in the September 16, 2005, issue ... that scientists eventually may be able to determine the ...
Other Biology News:Stressed cells spark DNA repair missteps and speed evolution 2Researchers report breakthrough against world’s deadliest viruses 2Computers close in on protein structure prediction 2Computers close in on protein structure prediction 3Computers close in on protein structure prediction 4
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: